- NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS
-
The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.
- -
-
Page/Page column 54-55; 102; 267; 275; 297; 318-319
(2010/11/28)
-
- Fused pyridine derivatives useful as angiotensin II antagonists
-
The invention concerns pharmaceutically useful compounds of the formula I, in which Q, X, Z, G1, G2, G3 and G4 have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions
- -
-
-
- 1,6-NAPHTHYRIDONE DERIVATIVES HAVING ANGIOTENSIN II ANTAGONIST ACTIVITY
-
The invention concerns pharmaceutically useful compounds of the formula I, in which R 1, R 2, R 3, R 4, Ra, Rb, A, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
- -
-
-
